Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Inclusion Criteria: * Subjects must be currently participating in the 20040138 Amgen study * Subjects must sign the informed consent before any study specific procedures are performed. Exclusion Criteria * Subjects with any prior diagnosis of bone metastasis * Known hypocalcemia * Developed sensitivity to mammalian cell derived drug products during the 20040138 study * Currently receiving any investigational product other than denosumab or having received any investigational product during the 20040138 study * Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures